GlassScriptPhysician profile
Farhad S Irani
NPI 1982767265
$4,006.28
in general payments reported to CMS, 2019-2025
31 companies · $400 in 2025
The $400 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $408 · 2020: $443 · 2021: $634 · 2022: $816 · 2023: $789 · 2024: $518 · 2025: $400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,685 · Education: $20.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,685.34 |
| Education | $20.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,007.75 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Novo Nordisk INC | $954.63 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Astrazeneca Pharmaceuticals LP | $288.00 | 2019-2024 | Breztri, Farxiga |
| Novartis Pharmaceuticals Corporation | $232.06 | 2024-2025 | |
| Abbvie INC. | $201.63 | 2021-2025 | |
| Abbott Laboratories | $144.46 | 2021-2023 | Freestyle Libre 2 |
| Merck Sharp & Dohme LLC | $115.72 | 2020-2023 | Verquvo |
| Lilly USA, LLC | $106.89 | 2022-2023 | Mounjaro, Jardiance |
| Sanofi-Aventis U.S. LLC | $99.31 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $95.00 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $91.58 | 2021-2025 | Unithroid |
| Amarin Pharma, INC. | $90.45 | 2019-2022 | |
| Pfizer INC. | $61.39 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $56.59 | 2023-2024 | Xarelto |
| Glaxosmithkline, LLC. | $51.42 | 2019-2023 | Shingrix, Arexvy, Trelegy Ellipta |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $45.20 | 2022 | |
| Corcept Therapeutics | $37.19 | 2024 | Korlym |
| Dexcom, INC. | $33.75 | 2022-2024 | Dexcom G6 Transmitter |
| Amgen INC. | $33.32 | 2023 | Otezla, Repatha |
| Radius Health, INC. | $30.91 | 2022 | |
| Gilead Sciences, INC. | $28.99 | 2025 | |
| Solventum Corporation | $27.22 | 2024 | Promogran Prisma, Activ.A.C., Adaptic |
| Sanofi Pasteur INC. | $26.79 | 2020 | |
| Cvrx, INC. | $22.99 | 2025 | Barostim Neo System |
| Exact Sciences Corporation | $21.82 | 2025 | Cologuard Collection Kit |
| Nevro Corp. | $21.41 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $18.42 | 2023 | Evkeeza |
| Idorsia Pharmaceuticals US INC | $16.71 | 2023 | Quviviq |
| Irhythm Technologies, INC. | $16.45 | 2022 | |
| Xeris Pharmaceuticals, INC. | $16.15 | 2022 | |
| Genentech USA, INC. | $12.08 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farhad Irani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.